Indeed, sustained ErbB2/neu signaling stimulates proliferation, inhibits apoptosis, confers chemotherapy resistance, and promotes invasion and metastasis of breast cancer cells [38,39,40]. Here, ERBB2 is linked to breast carcinoma.